Skip to main content

Advertisement

Table 4 Cost and proportion of patients for empiric use of Voriconazole vs. LAmB

From: Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey

Outcome Voriconazole LAmB
Proportion (%) Cost (TL) Proportionate cost (TL)* Proportion (%) Cost (TL) Proportionate cost (TL)*
No baseline fungal infection
Successful treatment 24.58 11,551 2,839 29.62 19,492 5,774
Mortality 7.95 11,551 919 5.92 19,492 1,155
Breakthrough fungal infection 1.93 29,777 574 4.98 31,593 1,572
Premature discontinuation 9.88 30,179 2,982 6.64 29,784 1,976
Persistent fever 52.53 30,350 15,943 51.42 30,075 15,465
Baseline fungal infection
Successful treatment 1.45 11,551 167 0.95 25,832 245
Mortality 0.00 0 0 0.00 0 0
Persistent baseline fungal infection 1.69 24,400 412 0.47 36,207 172
Total 100.00 -- 23,835 100.00 -- 26,358
  1. *Individual costs may not sum to actual total as all figures are rounded to the nearest full Turkish Lira (TL).